Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Charles River Laboratories International, Inc.NYSE: CRL

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 48.49M shares fell 1.7% year over year, ahead of the -3.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.7% holds above the trailing-twelve-month pace of -3.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
48.49M-0.9% QoQ
Last fiscal yearDec 2025
49.56M-4.0% YoY
LTMJun 2026
49.02M-3.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.7%——
1 year-4.0%——
3-year CAGR-1.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
49.56M USD
Year-over-year change
-4.0%
4-year CAGR
-0.9%

Weighted Avg Shares (Diluted) vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 weighted avg shares (diluted) of 49.02M shares is the 3rd highest of the 4 companies compared; the peer median is 77.92M shares.
  • Its year-over-year change of -3.4% is the 2nd highest of 4, against a peer median of -4.8%.
  • Over three fiscal years its annual growth of -1.1% compares with a peer median of -1.4%.
CRL Competitors Peer median
Weighted Avg Shares (Diluted) for CRL and competitors
Company Period LTM YoY 3-year CAGR
CERTCertara, Inc.LTM Mar 2026159.92M -0.6%+0.2%
ICLRICON Public Limited CompanyLTM Jun 202677.92M -4.8%-1.4%
CRLCharles River Laboratories International, Inc.LTM Jun 202649.02M -3.4%-1.1%
MEDPMedpace Holdings, Inc.LTM Sep 202628.76M -6.5%-4.3%
Peer median (excluding CRL) 77.92M-4.8%-1.4%

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.54B3.98B4.13B4.05B4.02B
Cost of Revenue2.21B2.51B2.63B2.72B2.79B
Gross Profit1.33B1.46B1.5B1.33B1.23B
Gross Margin37.7%36.8%36.4%32.9%30.5%
Research & Development00000
Selling, General & Admin619.92M665.1M747.86M751M743.07M
Operating Expenses744.78M811.68M885.3M1.1B717.73M
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
EBITDA820.16M986.15M1.03B581.14M410.84M
EBITDA Margin23.2%24.8%25.0%14.3%10.2%
Operating Income589.86M650.98M617.26M227.35M507.84M
Operating Margin16.7%16.4%14.9%5.6%12.6%
Interest Income652K780K5.2M8.58M4.94M
Interest Expense73.91M59.29M136.71M126.29M107.03M
Other Income / Expenses(109.15M)(27.99M)(35.98M)(134.23M)(607.34M)
Income Before Tax480.71M622.99M581.28M93.11M(99.5M)
Pre-Tax Margin13.6%15.7%14.1%2.3%-2.5%
Income Tax Expense81.87M130.38M100.91M67.82M42.66M
Net Income390.98M486.23M474.62M10.3M(144.34M)
Net Margin11.0%12.2%11.5%0.3%-3.6%
EPS (Basic)7.779.579.270.20(2.91)
EPS (Diluted)7.609.489.220.20(2.91)
Weighted Avg Shares50.29M50.81M51.23M51.38M49.56M
Weighted Avg Shares (Diluted)51.43M51.3M51.45M51.63M49.56M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.